Skip to main
EOLS

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evolus is positioning itself well within the competitive market of injectable neurotoxins and HA gels, with key advantages such as the only HA gel with a weight loss mention in its label and potential expansion into biostimulators and hair procedures. Additionally, the company has a strong commercial infrastructure and capital structure to support future growth. With a stable neurotoxin market and increasing interest in aesthetic treatments for volume loss, Evolus is poised for continued success and potential market share gains in the future.

Bears say

Evolus is currently performing well in the medical aesthetics market with their two commercially available products, Jeuveau and Evolysse, contributing positively to their YoY revenue growth. However, their high operating expenses and risks such as potential supply chain challenges and slower-than-expected ramp of Evolysse could hinder their future financial success. Their current valuation may be attractive, but their outlook may be impacted by a deteriorating consumer spending environment and competition in the market.

Evolus (EOLS) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Evolus (EOLS) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.